FPGS and acute lymphoblastic leukemia: Subsequently, a clinical trial found that the overexpression of FPGS’s novel variant was associated with lower accumulation of MTX-polyglutamylation and poorer response to MTX treatment, hence promoting MTX resistance in ALL patient cohorts [133].